



Oculus Mourns the Loss of Chief Scientific Officer Professor Ramin Tadayoni

Apr 22, 2024

ZUG, Switzerland, April 22, 2024 -- Oculus Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculus" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, mourns the loss of the Company's Chief Scientific Officer, Professor Ramin Tadayoni, M.D., Ph.D., who passed away unexpectedly on April 19, 2024.

"It is with immense sadness that we mourn the sudden passing of Prof. Ramin Tadayoni. Ramin was a highly accomplished and world renowned retina specialist that, as an advisor, played a key part in Oculus progress since its inception, and most recently as its newly appointed CSO," said Riad Sherif M.D., Chief Executive Officer of Oculus. "He was truly a luminary in the field of ophthalmology and, in addition to his scientific achievements, he will be remembered for his kindness, mentorship and unwavering commitment to advancing the field and bettering patients' lives. Prof. Tadayoni is leaving behind a profound legacy and we will be forever grateful for all his contributions. We extend our sincere and deepest condolences to his family, friends and all his colleagues during this difficult time."

Prof. Tadayoni was appointed as CSO of Oculus in February 2024. At the time, he served as the President of EURETINA, the European Society of Retina Specialists and the Retina Department Chairman of Rothschild Foundation Hospital, including the French Myopia Institute. Prior, he was also Chief of the Department for Lariboisière university hospitals and Saint-Louis hospital and Professor of Ophthalmology at University Paris-Cité. Prof. Tadayoni has been a Principal Investigator in numerous trials and served as an advisor for companies in the ophthalmology space for over two decades, including his role as Co-Chair of the Oculus Scientific Advisory Board. He was a passionate physician and researcher, authoring over 140 medical and scientific articles and making numerous contributions to ophthalmology textbooks. He was the recipient of numerous awards, including the American Academy of Ophthalmology Achievement Award and the prestigious Jules Gonin Award from the Retina Research Foundation. Dr. Tadayoni completed his medical degree and internship at Paris V University. His retina fellowship was completed at Lariboisière University Hospital while simultaneously pursuing his Ph.D. in Science at Paris VII University and the Paris Vision Institute.

Oculus Contacts

Oculus is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculus' highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNF α eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculus' goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculus.com

Oculus Contacts

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculus.com

Investor & Media Relations

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577